Navigation Links
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Date:5/30/2008

Summary: Genmab has Initiated a Phase I/II Study of Zalutumumab in Combination With Irinotecan Chemotherapy to Treat Refractory Colorectal

Cancer Patients

COPENHAGEN, Denmark, May 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr(TM)) in combination with irinotecan chemotherapy to treat colorectal cancer (CRC). The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy.

"We are glad to expand the zalutumumab program with this new indication," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the trial This open label study consists of two parts. In both parts of the study, patients will receive weekly doses until disease progression. Part 1 will include 3 to 15 patients who will receive weekly doses of first 8mg/kg of zalutumumab in combination with bi-weekly irinotecan and if safe patients will subsequently receive 16 mg/kg zalutumumab in combination with irinotecan.

Part 2 will be an open label randomized parallel group enrolling 14 to 82 patients pending the number of treatment arms and early termination from part 1. Patients in part 2 will receive weekly doses of zalutumumab with or without bi-weekly irinotecan administration until disease progression. In total a maximum of 97 patients will be enrolled into the study.

Safety data from Part 1 of the trial will be evaluated by an independent data monitoring committee who will determine if it is safe to begin Part 2. The objective of the study is to evaluate the safety and efficacy of zalutumumab in combination with irinotecan. The primary endpoint of the study is adverse events.

About Colorectal Cancer

CRC is a public health problem in developed countries. Although potentially curable in early stages, a proportion of pa
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Seoul Semiconductor announced the expansion ... in the lighting market. In recent months, ... technology in emerging markets such as Russia, South ... of applications such as streetlight and area lighting, ... First launched in 2005 the Acrich technology from ...
(Date:4/23/2015)... 23, 2015 Athena San Diego, an ... executive women in San Diego’s technology and life science ... Pinnacle Awards at their Gala on April 30, 2015 ... now at http://athenasd.org/events/ , The Pinnacle Awards ... San Diego vision of fostering networking, risk taking and ...
(Date:4/23/2015)... ON , April 23, 2015 /CNW/ - A ... sustainable packaging award from North America,s ... Brandcheck Competitor Comparison won Silver in the "Sustainability, ... The Brandcheck "Competitor Comparison" is a ... of North American and Global peers. This benchmarking ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4
... Sensus Healthcare is proud to announce ... South Beach Symposium™ in Miami Beach, FL ... a comprehensive session with three non-overlapping tracks in clinical ... superficial radiotherapy (SRT) with their SRT-100™ advanced platform as ...
... YORK, Feb. 17, 2011 Reportlinker.com announces that ... its catalogue: Targeted Therapeutics- Advancement ... Drive the Market http://www.reportlinker.com/p0397055/Targeted-Therapeutics--Advancement-in-Gene-Therapy-and-Stem-Cell-Therapy-will-Drive-the-Market.html ... Therapy and Stem Cell Therapy will Drive the ...
... someday become one of the most effective weapons to stop ... of lives in Haiti since the devastating earthquake last year. ... would allow relief workers to test water sources that could ... sugar dextran is coated onto iron oxide nanoparticles and then ...
Cached Biology Technology:Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™ 2Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 2Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market 3Special sugar, nanoparticles combine to detect cholera toxin 2Special sugar, nanoparticles combine to detect cholera toxin 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... in Yemen, is threatening livelihoods, in a country where rearing ... a Ministerial delegation was at the IAEA in Vienna, Austria, ... fight the deadly pest. The menacing fly lays its ... animal. The maggots then feast off the living flesh, and ...
... May 5 bioMETRX Inc., (OTC,Bulletin Board: BMRX), ... today announced that it has closed an interim,round ... of previous angel,accredited investors., "We have tremendous ... company has demonstrated to us the ability to ...
... a plant produces is closely tied to its sexual ... the evolution of such intimate relationships between plants and ... its kind and published online in the British Ecological ... recent dramatic decline in certain bumblebee species found in ...
Cached Biology News:Screw worm outbreak in Yemen 2Screw worm outbreak in Yemen 3bioMETRX, Inc. Closes Angel Round of Funding 2Ecologists tease out private lives of plants and their pollinators 2
... Product Goat polyclonal to Cholesterol Oxidase ... Reactivity / Specificity Cross-reacts with bacteria. ... Background Information Cholesterol oxidases exist as ... and are implicated in bacterial pathogenesis. In ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: